Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America
Open Access
- 1 July 2022
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200068
Abstract
PURPOSE: Infections are a significant cause of morbidity and mortality in patients with multiple myeloma (MM). In Latin America, data on infectious complications in this patient population are lacking. METHODS: We conducted a prospective cohort study of patients with newly diagnosed MM (NDMM) in seven Latin American countries between June 2019 and May 2020. Patients with active disease, on active therapy, and with a follow-up of 6 months from the time of diagnosis were included. Our primary end point was the number of infectious events that required hospitalization for ≥ 24 hours. RESULTS: Of 248 patients with NDMM, 89 (35.9%) had infectious complications (113 infectious events), the majority (67.3%) within the first 3 months from diagnosis. The most common sites of infection were respiratory (38%) and urinary tract (31%). The microbial agent was identified in 57.5% of patients with gram-negative bacteria (73.5%) as the most common pathogen. Viral infections were infrequent, and no patients with fungal infection were reported. In the multivariable analysis, diabetes mellitus (odds ratio [OR], 2.71; 95% CI, 1.23 to 6.00; P = .014), creatinine ≥ 2 mg/dL (OR, 4.87; 95% CI, 2.29 to 10.35; P < .001), no use of trimethoprim-sulfamethoxazole prophylaxis (OR, 6.66; 95% CI, 3.43 to 12.92; P < .001), and treatment with immunomodulatory drugs (OR, 3.02; 95% CI, 1.24 to 6.29; P = .003) were independent factors associated with bacterial infections. At 6 months, 21 patients (8.5%) had died, 47.6% related to infectious complications. CONCLUSION: Bacterial infections are a substantial cause of hospital admissions and early death in patients with NDMM. Antibiotic prophylaxis should be considered to reduce infectious complications in patients with MM.Keywords
This publication has 40 references indexed in Scilit:
- Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideLeukemia & Lymphoma, 2011
- Infections in Patients With Multiple MyelomaSeminars in Hematology, 2009
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX StudyJournal of Clinical Oncology, 2008
- Immunodeficiency and immunotherapy in multiple myelomaBritish Journal of Haematology, 2007
- Risk of bacteraemia and mortality in patients with haematological malignanciesClinical Microbiology and Infection, 2006
- Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working PartyJournal of Clinical Oncology, 2005
- Renal, hematologic and infectious complications in multiple myelomaBest Practice & Research Clinical Haematology, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Immunological factors and risk of infection in plateau phase myeloma.Journal of Clinical Pathology, 1995
- Influence of treatment and response status on infection risk in multiple myelomaThe American Journal of Medicine, 1981